Jean Wei is a biotechnology professional with over 15 years of experience in areas such as molecular cloning, gene expression, immunotherapy, antibody research, and protein purification. She currently works as a QC Associate at PCT Progenitor Cell Therapy where she develops and optimizes cell-based assays and performs quality testing on therapeutic cell products. Previously, she held research roles at several biotech companies where she gained extensive experience in antibody purification, cell culture techniques, and assay development.

1. JEAN WEI
Palo Alto ∙ (408) 966-1798 ∙ jiejeanwei@gmail.com
BIOTECHNOLOGY PROFESSIONAL
Resourceful, self-motivated and diligent professional with 15+ years of experience in Biotechnology. Excellent
analytical expertise coupled with proven technical knowledge, encompassing molecular cloning, gene expression,
Immunotherapy, antibody research, protein purification, characterization and more. Accomplished at building
rapport with management and colleagues from all levels underscored by the ability to simplify and communicate
complex scenarios. Adept at working in an environment requiring problem solving, with demonstrated
effectiveness to multitask in a competitive, high-impact, and fast-paced environment. Well organized, juggling
multiple priorities simultaneously utilizing good judgement and time-management.
AREAS OF STRENGTH
✓ FACS Calibur/ CANTO II
✓ ELISA, HPLC, AKTA Explorer
✓ Cancer Biology/ Immunology
✓ Protein Chemistry
✓ Antibody conjugations/ Fab
✓ CBC/ Bioanalyzer/ Endosafe
✓ LabChip GXII Caliper system
✓ Cell cultures
✓ Western blotting
✓ Molecular cloning
✓ PCR/ sequencing
✓ Nucleic acid hybridization
● Expertise in Flow cytometry, cell based assays,Hybridoma technology, cell culture, etc.
● Extensive experience in antibody research; standardized procedures for Endotoxin testing and removal;
successfully utilize AKTA Explorer systemfor antibody aggregation testing and removal.
● Successfully initiated, applied and optimized glycan profiling and charge heterogeneity assay onto the LabChip
GXII/Caliper system.
● Set up and standardized Bovine IgG ELISA analysis for purified antibody proteins.
● Performed independent study on In Vivo regulation of DNA Methyltransferase I expression; successfully
designed tissue specific knock out of the DNA Methyltransferase gene using Lac I system. Thorough training
and knowledge in molecular cloning, PCR, sequencing and Nucleic acid hybridization, etc.
● Established Her-2/neu overexpressing cell line for in vivo and in vitro study on its potentialrole in angiogenesis.
Excellent understanding and hands on experiences in cancer biology, Immunohistochemistry, assay
development. Experience on Islet cell proliferation and characterization.
● Substantial knowledge and background in the study ofImmunology and human disease.
● Insights in clinical development and regulatory issues,with quick thinking and exemplary interpersonal skills
when coordinating with multi-disciplinary project teams.
● Good technical writing skills; wrote series of SOPs for standardize analysis, assays and testing.
PROFESSIONAL EXPERIENCE
PCT Progenitor Cell Therapy, Mountain View, CA November,2015 - Present
QC Associate III
Cell therapy; Develop and optimize cell based assays; Perform purity analysis, apoptosis and
suppression assays, T cell phenotype analysis using Flow Cytometry, FACS Calibur/ CANTO
II; QC testing on therapeutic cell product using ELISA, CBC, Nucleocounter, Endosafe, etc.
B.M.S. - Redwood City, CA Jan 2002 – May 2015
Research Associate IV
Provide the best available purified antibody protein, in terms of quality and quantity; ELISA, In Vitro assays.

2. ● Purify antibodies to support drug development projects at various stages (~20 antibody proteins/ human,
mouse and rat IgGs purified each week with 15 antibodies per week as maxim approach for general
professionals).
● Initiated, set up and performed high throughput parallel protein purification on "Protein maker system";
improved the efficiency by 50% of time and cost.
● Successfully optimized, standardized and wrote SOPs for antibody purification, Endotoxin testing,
Endotoxin removal; successfully reduced aggregation for the purified antibody proteins through AKTA
explorer system; provide better purified antibodies for downstream biological analysis more efficiently
while cost effective.
● Initiated and standardized purity, glycan profiling and charge heterogeneity assay on LabChip GXII /
Caliper system / Bioanalyzer; substantially reduced time with increased sensitivity and reproducibility as
compared to the traditional methodology.
● Provide consistent service upon request with great quality for antibody conjugations: APC, PE, FITC,
Biotin, AlexaFluor, etc. Excellent experience with Fab preparation with close to 70% recovery rate on
average; antibody solubility and stability study.
VIVO RX, INC. - Santa Monica, CA June 2000 - Jan 2002
Senior Research Associate
● Diabetic research study; Islet cell proliferation and characterization; identify signals inducing cell
aggregation and Insulin expression; in charge of Flow cytometry analysis, etc.
U.S.C. - Los Ángeles, CA Sept 1996 - Feb 2000
Graduate Student
● Successfully performed independent study on potential role of Her-2/neu in angiogenesis; unlike the
conventional approach, we propose that overexpression of oncogene may stimulate tumor development
by facilitating angiogenesis. We established cell lines that overexpress Her-2/neuandstudied its potential
regulatory function in angiogenesis and underlying mechanism. By taking a different approach, using
chick embryo-a model that is analogous to transgenic mice, we further confirmed that Her-2/neu
overexpressing cells are highly tumorigenic. The study was also investigated on a molecular level by
screening the difference in the expression of various angiogenesis inducers and inhibitors for Her-2/neu
positive (NIH.189) vs the negative control (NIH.3T3) cells. 08/1998 - 02/2000
● In Vivo regulation of DNA methyltransferase I Expression. The problem of study the Dnmt gene is that
the homozygous knock out of the gene is embryonic lethal and the heterozygous knock out has no
phenotype. By designing tissue specific knock out using LacI system, we were able to further study the
function of DNA Methyltransferase gene. A few modifications were made to develop optimal Lac I: by
lowered DNA Methylation (by removing CpGs), introducing optimal KOZAK and codon optimization to
achieve efficient expression; introduced nuclear localization signal and tight binging mutation to achieve
optimal function of the gene, together with the tissue specific promoter to give a tissue specific expression.
09/1997-08/1998
Millennium Pharmaceuticals, Inc. - Cambridge, MA
Human genome mapping by Microsatellites, genetic linkage analysis and mutation detection for Asthma patients
Harvard University/ Biological Laboratories, Cambridge, MA
Human genome mapping project, participated in successfully complete the genome mapping project;
Evolutionary genetics of insertion sequences and plasmids in E. Coli
M.I.T. - Cambridge, MA
Biotechnology process engineering center / Mechanism of cosolvent PEGenhanced refolding of Bovine
carbonic anhydrase B; Dupont Fellow: Polymer Science & Technology, M.I.T.
EDUCATION & TRAINING
Masters in Biochemistry & Molecular Biology - U.S.C.
References available upon request